Epigral Share Price

Specialty Chemicals company Epigral announced Q4FY26 & FY26 results Standalone Financial Highlights Revenue from operations for Q4FY26 was Rs 736.16 crore, an increase of 17.29% YoY compared to Rs 627.63 crore in Q4FY25 and a growth of 23.28% QoQ against Rs 597.12 crore in Q3FY26. Total income for Q4FY26 stood at Rs 735.59 crore, up 16.57% YoY from Rs 631.03 crore and up 22.05% QoQ from Rs 602.68 crore. Net Profit after tax for Q4FY26 was Rs 81.93 crore, reflecting a decrease of 5.41% YoY from Rs 86.62 crore but a substantial growth of 109.27% QoQ from Rs 39.15 crore. For FY26, Standalone Revenue from operations was Rs 2,527.18 crore, showing a marginal decline of 0.90% compared to Rs 2,550.13 crore in FY25. Annual Net Profit after tax for FY26 reached Rs 333.01 crore, down 6.64% from Rs 356.70 crore in the previous financial year. Earnings per share (not annualized) for Q4FY26 was Rs 18.99, while the annual EPS for FY26 stood at Rs 77.19. Consolidated Financial Highlights Consolidated Revenue from operations for Q4FY26 reached Rs 736.16 crore, marking a 17.29% YoY increase from Rs 627.63 crore and a 23.28% QoQ increase from Rs 597.12 crore. Total consolidated income for the quarter was reported at Rs 735.59 crore, up 16.57% YoY and 22.05% QoQ. Consolidated Net Profit after tax for Q4FY26 was Rs 80.95 crore, representing a 6.84% YoY decline from Rs 86.89 crore but an increase of 107.01% QoQ compared to Rs 39.11 crore. For the full year FY26, Consolidated Revenue from operations stood at Rs 2,527.18 crore, compared to Rs 2,550.13 crore in FY25, a decrease of 0.90%. Annual Consolidated Net Profit after tax for FY26 was Rs 331.97 crore, a 7.19% decrease from Rs 357.69 crore in FY25. Consolidated annual earnings per share for FY26 was Rs 76.95. Business Highlights Segment Performance: The company’s business activities fall within a single business segment, namely "Chloro Alkali & its Derivatives," which accounts for its entire operational performance. Dividend: The Board of Directors recommended a final dividend of Rs 5.00 (50%) per Equity Share of face value of Rs 10 each for FY26. Taxation: Effective from FY26, the company exercised the option permitted under Section 115BAA of the Income-tax Act, 1961. This resulted in the recognition of a one-time deferred tax credit of Rs 80.87 crore in the Statement of Profit and Loss. Investment in Renewable Energy: During FY26, the company entered into a Share Subscription and Shareholders' Agreement to invest Rs 0.13 crore for a 26% equity stake and Rs 21.25 crore in Optionally Convertible Debentures of Pro-Zeal Green Power Ten Private Limited. The investment supports a 19.80 MW Wind Solar Hybrid Power plant in Gujarat. Labour Codes: The company assessed the incremental liability for gratuity and leave encashment regarding the new Labour Codes notified on November 21, 2025, and concluded the impact is not material to the financial results. Maulik Patel, Chairman & Managing Director, Epigral, said: “In Q4FY26, we delivered record revenue of Rs 736 crore, driven by a 15% sequential increase and 14% YoY growth in volumes. This performance reflects strong demand conditions and a full recovery post-scheduled maintenance in Q3. Improved utilization levels and stabilization in raw material costs supported EBITDA margins of 23%. While FY26 saw some impact due to an extended monsoon and planned maintenance in the first half, demand recovery began in November and strengthened through Q4. We expect this momentum to continue into FY27, subject to global macro conditions”. “Our diversified product portfolio continues to provide resilience amid geopolitical uncertainties, including developments in West Asia. At the same time, our ongoing capex projects for Epichlorohydrin and CPVC expansion are progressing as planned and within budget. Once commissioned, these plants will address India’s growing demand and enhance our financial performance. With these projects nearing completion and a pipeline of new initiatives focused on further integration, we are well-positioned to deliver consistent growth and long-term value for our stakeholders.” Result PDF

• Trendlyne
• 4 weeks ago

Specialty Chemicals company Epigral announced Q3FY26 results Plant utilization stood at 78% similar to previous quarter. The company posted a revenue of Rs 603 crore for Q3FY26 as against Rs 649 crore recorded in Q3YF25. EBITDA margin stood at 17% vs 23% in Q2FY26 on account of drop in realizations and increase in cost of raw materials. PAT stood at Rs 39 crore compared to Rs 104 crore in Q3FY25. Maulik Patel, Chairman & Managing Director, Epigral said: “This quarter delivered marginal sequential topline growth. While demand softened before mid-November due to extended monsoon conditions, the market has strengthened notably since then, and we anticipate sustained positive momentum ahead. Margins in Q3FY26 reflected temporary pressures from softer realizations on select products, elevated raw material costs, and inventory dynamics. With the improving market scenario, we anticipate positive outcomes starting Q4FY26. Our capacity expansion projects for CPVC, Epichlorohydrin, and Wind Solar Hybrid Power Plant are progressing smoothly on schedule, set for timely commissioning. These initiatives will drive growth from FY27 onwards. We're also advancing new projects and look forward to sharing updates soon. We remain committed to our journey of scalable, profitable growth optimizing capital allocation, enhancing integration, and delivering lasting value for all stakeholders.” Result PDF

• Trendlyne
• 4 months ago

Specialty Chemicals company Epigral announced Q2FY26 results Q2FY26 Financial Highlights: Plant utilization stood at 78% vs 73% in previous quarter Sales volume grew by 2% compared to previous quarter QoQ Revenue dropped by 4% to Rs 589 crore on account of drop in realizations in few of the products EBITDA margin stood at 23% vs 27% in Q1FY26 on account of drop in realizations and lower utilization PAT stood at Rs 51 crore H1FY26 Financial Highlights: Plant utilization stood at 75% vs 83% in H1FY25 Sales volume dropped in H1FY26 majorly on account of off season for few of the products and we expect sales volume to improve in H2FY26 Revenue dropped by 6% to Rs 1,204 crore on account of drop in sales volume EBITDA margin stood at 25% vs 28% in H1FY25 on account of drop in realizations and lower utilization Net Debt stood at Rs 496 crore vs Rs 489 crore as on 31st March 2025 ROCE stood at 21% and Net Debt/EBITDA stood at 0.8x Maulik Patel; Chairman and Managing Director – Epigral said: “This quarter ended with lower revenue on account of low sales volume and drop in realization of few products. Volume drop was majorly on account of extended monsoon which is off season for few products. Overall plant utilization stood at 75% for H1FY26 and we expect utilization to improve in H2FY26, as extended monsoon is over and maintenance work at plant is also completed, resulting in better H2 compared to H1. Our project to expand capacity of CPVC, Epichlorohydrin and Wind Solar Hybrid power plants are moving as per schedule and expected to be commissioned within committed timelines. These projects will drive growth from FY2027 onwards. We have further moved a step closer for the new projects. We will be announcing the same once it is freezed and approved by the board. We will continue to advance along our path of scalable profitable growth, optimize capital allocation, strengthen our integration, and create enduring value for all stakeholders.” Result PDF

• Trendlyne
• 6 months 3 weeks ago